Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

100816

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Terminal Illnesses
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what guidance his Department has issued to health technology appraisal committees on application of NICE's end of life criteria when appraising treatments for patients with terminal illness.
tabling member constituency	Redcar
tabling member printed	Ian Swales
uin	211809
answer	answer is ministerial correction date of answer 28/10/2014 answer text <p>The Department has not issued any such guidance. The National Institute for Health and Care Excellence is an independent body and is responsible for the development of its methods and processes.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 28/10/2014 14:56:20 answering member 4020 label Biography information for George Freeman
tabling member	4045 label Biography information for Ian Swales

100817

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Terminal Illnesses
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what rationale lies behind NICE's advice that end-of-life criteria should only apply to medicines that extend life by at least three months.
tabling member constituency	Redcar
tabling member printed	Ian Swales
uin	211807
answer	answer is ministerial correction date of answer 28/10/2014 answer text <p>In January 2009, the National Institute for Health and Care Excellence (NICE) issued supplementary advice to its appraisal committees on appraising treatments which may be life-extending for patients, with short life expectancy, and which are licensed for indications affecting small numbers of patients with incurable illnesses.</p><p> </p><p> </p><p> </p><p>This sets out the following three criteria that must all be satisfied for this supplementary advice to be applied:</p><p> </p><p>- the treatment is indicated for patients with a short life expectancy, normally less than 24 months;</p><p> </p><p>- there is sufficient evidence to indicate that the treatment offers an extension to life, normally of at least an additional three months, compared to current NHS treatment; and</p><p> </p><p>- the treatment is licensed or otherwise indicated, for small patient populations.</p><p> </p><p> </p><p> </p><p>These criteria were developed following public consultation and set out the circumstances when NICE considers it is appropriate for its appraisal committees to apply greater flexibility in their appraisal of these treatments.</p><p> </p><p> </p><p> </p><p>The advice has now been incorporated chapter 6 of <em>Guide to the methods of technology appraisal 2013 </em>which can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/article/pmg9/chapter/6-the-appraisal-of-the-evidence-and-structured-decision-making" target="_blank">www.nice.org.uk/article/pmg9/chapter/6-the-appraisal-of-the-evidence-and-structured-decision-making</a></p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 28/10/2014 14:27:08 answering member 4020 label Biography information for George Freeman
tabling member	4045 label Biography information for Ian Swales

92242

registered interest
date	26/09/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will assess the effect of the National Institute for Health and Care Excellence's three-month end-of-life threshold on the number of treatments for advanced pancreatic cancer.
tabling member constituency	Redcar
tabling member printed	Ian Swales
uin	209582
answer	answer is ministerial correction date of answer 15/10/2014 answer text <p>Since the National Institute for Health and Care Excellence (NICE) issued its supplementary advice to its appraisal committees on the appraisal of life extending, end-of-life treatments in January 2009, NICE has not published final technology appraisal guidance on any treatments for advanced pancreatic cancer.</p><p> </p><p> </p><p> </p><p>NICE is currently developing technology appraisal guidance on two treatments for pancreatic cancer:</p><p> </p><p>- Abraxane (paclitaxel) in combination with gemcitabine for treating previously untreated metastatic adenocarcinoma of the pancreas (final guidance is expected in January 2015); and</p><p> </p><p>- Theraloc (nimotuzumab) for the first line treatment of metastatic pancreatic cancer (final guidance is expected in August 2015).</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/10/2014 15:33:22 answering member 4020 label Biography information for George Freeman
tabling member	4045 label Biography information for Ian Swales

92258

registered interest
date	26/09/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many drugs were approved by the Cancer Drugs Fund and subsequently rejected by NICE in the last 12 months.
tabling member constituency	Redcar
tabling member printed	Ian Swales
uin	209753
answer	answer is ministerial correction date of answer 15/10/2014 answer text <p>Since 1 September 2013, no cancer drugs have been added to the national list of approved cohort policies for drugs available through the Cancer Drugs Fund and subsequently not been recommended by the National Institute for Health and Care Excellence in final technology appraisal guidance.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/10/2014 15:22:31 answering member 4020 label Biography information for George Freeman
tabling member	4045 label Biography information for Ian Swales